AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02977923 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pharmacological treatment
Description: according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
Study NCT03414957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hormonal and biochemical blood tests and ultrasound scanning
Description: Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
Study NCT04505683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benapenem
Description: Benapenem for IV injection administered as a 1-gram IV infusion
Study NCT04505683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Ertapenem for IV injection administered as a 1-gram IV infusion
Study NCT03777449 — intervention group
Intervention type: RADIATION
Intervention: CBCT
Description: Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
Study NCT02656927 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Yoga Condition
Study NCT02656927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Condition
Study NCT02077933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpelisib
Description: alpelisib is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation and Day 1 of Cycle 1 in the dose expansion.~In the doublet dose escalation, the alpelisib starting dose is 300 mg. The alpelisib dose may be escalated or de-escalated, as needed.~In the triplet dose escalation part, the alpelisib starting dose is one dose level lower of the MTD as determined during the doublet escalation. The alpelisib dose may be escalated or de-escalated, as needed.~In the doublet dose expansion and triplet dose expansion (patients assigned to alpelisib, everolimus and exemestane), alpelisib is administered at the recommended dose determined in the dose escalation.~In the triplet dose expansion (patients assigned to alpelisib and exemestane), alpelisib is administered at a dose of 250 mg daily.
Study NCT02077933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: everolimus is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts.~In the dose escalation part, the everolimus starting dose is 2,5 mg. In the dose expansion part, everolimus is administered at the recommended dose determined in the dose escalation.
Study NCT02077933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
Study NCT01515527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18.
Study NCT01515527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18.
Study NCT01515527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
Study NCT03857789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: A 40 question frailty questionnaire.
Study NCT03857789 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: A 40 question frailty questionnaire.
Study NCT02460211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
Study NCT02460211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those randomized to the control arm will receive three placebo doses. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: +/- 200mg ritonavir NORVIR
Description: BID
Study NCT02631473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400mg Sustiva
Study NCT00536211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at \~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
Study NCT00536211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: oral tablet, 1000 mg daily for 17 days
Study NCT03445156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game
Description: Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
Study NCT02045381 — intervention group
Intervention type: PROCEDURE
Intervention: MRI Group
Description: A single research MRI
Study NCT03445156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controller
Description: Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.
Study NCT01030692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo groups will receive the same dosage throughout the study.
Study NCT01030692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine 3 mg
Description: The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
Study NCT01030692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huperzine A 0.4 mg
Description: The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
Study NCT01030692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine 6 mg
Description: The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
Study NCT01030692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huperzine A 0.8 mg
Description: The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
Study NCT02409511 — intervention group
Intervention type: OTHER
Intervention: non intervention
Study NCT00437216 — intervention group
Intervention type: DRUG
Intervention: Clobetasol Propionate, 0.05%
Description: Apply twice daily for 2 or 4 weeks as monotherapy
Study NCT00437216 — intervention group
Intervention type: DRUG
Intervention: Clobetasol propionate, 0.05% Spray
Description: Apply twice daily for 2 or 4 weeks as add-on therapy
Study NCT04120155 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dissection of the Inferior Pulmonary Ligament
Description: Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the dissection group, we will dissect the inferior pulmonary ligament during the surgery.
Study NCT04120155 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preservation of the Inferior Pulmonary Ligament
Description: Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.For the preservation group, we will preserve the inferior pulmonay ligament during the surgery.
Study NCT02439580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Annona muricata extract
Description: ethanol-soluble fraction of water extract
Study NCT02439580 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltose
Study NCT01699139 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: positional device
Description: Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.
Study NCT01699139 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: lumbar corset
Description: A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
Study NCT00491179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks
Study NCT00491179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks
Study NCT01621685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological/vaccine
Description: Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
Study NCT04684420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR RM Test
Description: Participants received a single oral dose of 500 mg of test Glucophage® XR RM tablet under fasting or fed conditions.
Study NCT04684420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage® XR Reference
Description: Participants received a single oral dose of 500 mg of reference Glucophage® XR tablet under fasting or fed conditions.
Study NCT02413437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CEUS guided biopsy
Description: Biopsy was operated under contrast-enhanced ultrasound-guided.
Study NCT02413437 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: US guided biopsy
Description: Biopsy was operated under conventional ultrasound-guided.
Study NCT02413437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT02413437 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Study NCT01345500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Carbohydrate, Lower Fat Diet
Description: Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
Study NCT01345500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate, Higher fat diet
Description: Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
Study NCT01345500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Counseling
Description: Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
Study NCT03728387 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates Exercise
Description: All evaluations of the individuals included in the study will be done by the physiotherapist.. For the second evaluation the same individuals will be visited by the same physiotherapist at least 7 days after the first evaluation and only the FAB-T scale will be applied. 34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section. Various exercise methods (clinical pilates exercises) and tools will be utilized to improve balance and mobility. Third assessment of FAB-T will be applied only to individuals participating in the 6-week exercise training program.
Study NCT02084446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
Study NCT02084446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Tacrolimus
Description: Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
Study NCT02084446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Tacrolimus
Description: Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
Study NCT02084446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
Study NCT02084446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
Study NCT02084446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
Study NCT02084446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
Study NCT02084446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Mycophenolate
Description: Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
Study NCT03889041 — intervention group
Intervention type: OTHER
Intervention: Quality of life assessment
Description: The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
Study NCT02765282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algorithm based programming using Kinesia-based assessment
Description: DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.
Study NCT02538302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minirin
Description: Minirin 5 to 10 mg daily for 6 months
Study NCT02538302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Oxybutynin 5 to 10 mg daily for 6 months
Study NCT00002550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Study NCT00002550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00002550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study NCT00002550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00002550 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00002550 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03765645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin + Tazobactam
Description: Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous
Study NCT02664116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac postassium powder for oral solution and placebo injection
Description: Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
Study NCT02664116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac intramuscular injection and placebo oral solution
Description: ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
Study NCT03426176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin nasal spray
Description: intranasal administration of oxytocin (24 IU)
Study NCT03426176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo treatment (placebo-control for oxytocin)
Description: intranasal administration of placebo nasal spray
Study NCT03426176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal placebo treatment (placebo-control for oxytocin)
Description: intranasal administration of placebo nasal spray
Study NCT03426176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATD treatment
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
Study NCT03426176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo treatment (placebo-control for ATD)
Description: oral administration of a tryptophan-balanced mixture (78.2g)
Study NCT03426176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo treatment (placebo-control for ATD)
Description: oral administration of a tryptophan-balanced mixture (78.2g)
Study NCT02393911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Oxalate Diet
Description: Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
Study NCT01362582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOF Kabiven
Description: SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
Study NCT03783949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
Study NCT03783949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
Study NCT03783949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
Study NCT03783949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)